Press Releases from ISA Pharmaceuticals (13 total)
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a…
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …
- Recognition for outstanding and innovative cancer research
Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that…
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ES …
Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has…
ISA Pharmaceuticals Reports Publication of Favorable Phase 2 Results of ISA101 p …
Leiden, The Netherlands, September 27, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced the publication of the results of a Phase 2…
ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer
Leiden, The Netherlands, May 23, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immune oncology company, today announced that Gerben Moolhuizen has been promoted from Chief…
ISA Pharmaceuticals Appoints Leon Hooftman as Chief Medical Officer
- Experienced Chief Medical Officer to advance ISA´s clinical pipeline -
Leiden, The Netherlands, April 30, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing…
ISA Pharmaceuticals' ISA101 Studied in Phase II Oropharyngeal Cancer Combination …
Leiden, The Netherlands, April 26, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections,…
Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg Un …
- Ceremony Conventio Medicinae held at University Medical Center
Leiden, The Netherlands, October 26, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that its…
Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at …
- Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor
Leiden, The Netherlands, September 4, 2017 – ISA Pharmaceuticals B.V., a clinical-stage…
Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be …
- Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer
Leiden, The Netherlands, May 23, 2017 – ISA Pharmaceuticals B.V., a clinical-stage…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Honored by …
-- Cornelis ("Kees") Melief receives lifetime achievement award for his work as a leading immuno-hematologist --
Leiden, The Netherlands, May 11, 2017 – ISA Pharmaceuticals B.V.,…
Go To Page:
